TY  - JOUR
AU  - Alonso-García, Miriam
AU  - Sánchez-Gastaldo, Amparo
AU  - Muñoz-Fuentes, Miguel A
AU  - Molina-Pinelo, Sonia
AU  - Boyero, Laura
AU  - Benedetti, Johana Cristina
AU  - Bernabé-Caro, Reyes
PY  - 2022
DO  - 10.3390/ph15050533
SN  - 1424-8247
UR  - http://hdl.handle.net/10668/21533
T2  - Pharmaceuticals (Basel, Switzerland)
AB  - Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy...
LA  - en
KW  - atezolizumab
KW  - immune checkpoint inhibitors (ICIs)
KW  - immunotherapy
KW  - nivolumab
KW  - non-small cell lung cancer (NSCLC)
KW  - real-world data
TI  - Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
TY  - research article
VL  - 15
ER  -